目的:通过Meta分析的方式评估服用益生菌是否对乳腺癌有积极影响。方法:荟萃分析遵循PRISMA声明的标准,检索中英文数据库,涉及以下数据库:PubMed、Embase、Cochrane Library、中国知网数据库(CNKI)、万方数据库和中文科技期刊(维普网)数据库等。检索时间自建库至2024年6月。收集所有评估乳腺癌患者中益生菌干预的随机对照实验,提取相关数据,进行荟萃分析。结果:最终19项干预研究被纳入荟萃分析,共1041例患者。结果显示:与对照组相比乳腺癌患者服用益生菌后在化疗后腹泻(OR = 0.16;95% CI: 0.07~0.38, P P = 0.01)、CD4+ T淋巴细胞水平(MD = 2.42;95% CI: 1.58~3.25;P + T淋巴细胞水平(MD= −1.42;95% CI: −2.33~−0.51;P = 0.002)等方面的差异具有统计学意义。但是两组患者在体质指数、肿瘤坏死因子-α的差异上没有统计学意义(P > 0.05)。结论:服用益生菌对乳腺癌患者的病情及预后有积极的影响。Objective: By means of meta-analysis to assess whether taking probiotics has a positive effect on breast cancer. Method: The meta-analysis followed the criteria stated by PRISMA and searched databases in both Chinese and English, including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, and Chinese Science and Technology Journal (VIP) Database. The search covered records from the inception of these databases up to June 2024. Collect all randomized controlled trials evaluating probiotic intervention in breast cancer patients, extract relevant data, and conduct a meta-analysis. Results: A total of 19 intervention studies involving 1041 patients were included in the meta-analysis. The results indicated that, compared to the control group, breast cancer patients who used probiotics exhibited statistically significant differences in several outcomes following chemotherapy: the incidence of diarrhea (OR = 0.16;95% CI: 0.07 to 0.38;P P = 0.01), CD4+ T lymphocyte levels (MD= 2.42;95% CI: 1.58 to 3.25;P + T lymphocyte levels (MD= −1.42;95% CI: −2.33 to −0.51;P = 0.002). However, there were no statistically significant differences between the two groups in terms of body mass index, tumor necrosis factor-α (P > 0.05). Conclusions: The intake of probiotics has a positive influence on the condition and prognosis of breast cancer patients.
暂无评论